Indications: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
Dosage: 100 mg orally twice daily with or without food. After four weeks, increase to 150 mg twice daily, if needed, to achieve platelet count at least 50 x 109/L as necessary to reduce the risk of bleeding.
Indications: Treatment of X-linked hypophosphatemia (XLH) in patients 1 year of age and older.
Dosage: Pediatric XLH: Starting dose regimen is 0.8 mg/kg of body weight rounded to the nearest 10 mg, administered every two weeks. Adult XLH: 1 mg/kg body weight rounded to the nearest 10 mg up to a maximum dose of 90 mg administered every four weeks.
Contraindications: Do not use Crysvita with oral phosphate and active vitamin D analogs. Do not initiate Crysvita if serum phosphorus is within or above the normal range for age. Contraindicated in patients with severe renal impairment or end stage renal disease.
Akynzeo (fosnetupitant and palonosetron, Helsinn Therapeutics)
Indications: Akynzeo for injection is indicated in combination with dexamethasone in adults for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
Dosage: One vial of Akynzeo for injection; reconstituted in 50 ml of 5% dextrose injection, USP, or 0.9% sodium chloride injection, USP, and administered as 30-minute infusion starting approximately 30 minutes prior to the start of chemotherapy.
Indications: Reduce blood phenylalanine concentrations in adult patients with phenylketonuria who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.
Dosage: 2.5 mg subcutaneously once weekly for four weeks.